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During heart transplantation, storage in cold preservation solution is thought 32 
to protect the organ by slowing metabolism; by providing osmotic support; and by 33 
minimising ischaemia-reperfusion (IR) injury upon transplantation into the 34 
recipient1,2. Despite its widespread use our understanding of the metabolic changes 35 
prevented by cold storage and how warm ischaemia leads to damage is surprisingly 36 
poor. Here, we compare the metabolic changes during warm ischaemia (WI) and 37 
cold ischaemia (CI) in hearts from mouse, pig, and human. We identify common 38 
metabolic alterations during WI and those affected by CI, thereby elucidating 39 
mechanisms underlying the benefits of CI, and how WI causes damage. Succinate 40 
accumulation is a major feature within ischaemic hearts across species, and CI slows 41 
succinate generation, thereby reducing tissue damage upon reperfusion caused by 42 
the production of mitochondrial reactive oxygen species (ROS)3,4. Importantly, the 43 
inevitable periods of WI during organ procurement lead to the accumulation of 44 
damaging levels of succinate during transplantation, despite cooling organs as 45 
rapidly as possible. This damage is ameliorated by metabolic inhibitors that prevent 46 
succinate accumulation and oxidation. Our findings suggest how WI and CI 47 
contribute to transplant outcome and indicate new therapies for improving the 48 
quality of transplanted organs. 49 
Hearts are transplanted following donation after brainstem death (DBD), or 50 
following donation after circulatory death (DCD)5-8. Cooling the heart at the onset of 51 
ischaemia remains the mainstay of organ preservation, although emerging technologies 52 
allow preservation of some organs under normothermic and/or normoxemic conditions8,9. 53 
Rapid cooling minimises periods of WI during transplantation, which causes primary 54 
graft non-function, delayed or poor initial graft function, or chronic graft dysfunction10,11. 55 
Here we investigated the metabolic alterations during WI that contribute to tissue injury 56 
upon transplantation and which are prevented by CI.  57 
We compared the metabolic profile of mouse hearts and in sections of pig and 58 
human myocardium under conditions that mimic cold organ storage during 59 
transplantation (CI; ~2˚C) and compared these with WI (37˚C) (Fig. 1a) over time. There 60 
was a much faster decline in ATP/ADP ratio during WI compared to CI in all three 61 
species (Fig. 1b-d), decreasing by over 50% during the first 5 min of WI while 5 min of 62 
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CI had a negligible effect. In CI heart contraction ceased within ~1–2 s, but in WI 63 
contraction continued for ~90 s, however ATP consumption by contraction during WI did 64 
not contribute to changes in ATP/ADP as preventing contraction by cardioplegia did not 65 
affect the ATP/ADP ratio (Supplementary Fig. 1a). The total amount of ATP and ADP 66 
(ΣATP + ADP) was also better maintained during CI than WI (Figs. 1e-g), while AMP 67 
accumulation was faster during WI than in CI (Supplementary Fig. 1b). Thus, CI 68 
preserves the tissue ATP/ADP ratio and slows the loss of adenine nucleotides. 69 
During ischaemia oxidative phosphorylation stops and glucose is no longer 70 
delivered by the blood, hence the ATP/ADP ratio is sustained by glycogen-fuelled 71 
glycolysis12, generating lactate (Supplementary Fig. 2a). Glycogen in the mouse and pig 72 
was more rapidly depleted during WI, but depletion halted, despite 20–25 % of the 73 
glycogen remaining (Supplementary Figs. 2b,c). During CI glycogen depletion was 74 
slower, but continued until all the glycogen was consumed (Supplementary Figs. 2b,c). 75 
During WI lactate initially accumulated but then plateaued, whereas during CI the rate of 76 
lactate build up was far slower, but continued throughout CI (Supplementary Figs. 2d-h). 77 
In the mouse lactate accumulation ceased when glycogen breakdown stopped (dashed red 78 
line; Supplementary Figs. 2b,d). The lactate/pyruvate and NADH/NAD+ ion intensity 79 
ratios both increased far more rapidly and extensively during WI than during CI in the 80 
mouse (Supplementary Figs. 2h,i). Measurement of glycolytic intermediates in the mouse 81 
heart showed an accumulation of the GAPDH substrate glyceraldehyde-3-phosphate 82 
during WI, but the loss of products downstream of 3-phosphoglycerate kinase, 3-83 
phosphoglycerate and phosphoenolpyruvate compared to CI (Supplementary Fig. 3). 84 
These two enzymes utilise NAD+ and ADP and thus are likely inhibited by an elevated 85 
NADH/NAD+ ratio and depletion of ADP (Supplementary Fig. 2a). This may slow 86 
glycolysis during WI, even though glycogen stores remain. Thus, during WI there was 87 
rapid glycogen depletion to drive glycolysis, which was slowed by CI.  88 
To assess ischaemic metabolism more broadly, we performed a liquid 89 
chromatography/mass spectrometry (LC/MS)-based metabolomics analysis of mouse, pig 90 
and human heart tissue at various times under CI and WI (Supplementary Data 1a-c). 91 
Fifty-four metabolites were detected ubiquitously at up to 30 min WI and 480 min CI and 92 
changes in their abundance are presented as a heat map, demonstrating a similar overall 93 
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profile in mouse, pig and human heart tissue (Supplementary Fig. 4). We expanded the 94 
metabolome coverage to 107 metabolites for the mouse samples by a second LC/MS 95 
analysis which generated an extended heat map (Supplementary Fig. 5).  96 
To compare how these metabolites changed between WI and CI (Supplementary 97 
Data 2) we generated volcano plots for mouse, pig and human heart tissue (Figs. 2a-c). 98 
Strikingly, most of the significant metabolic changes between WI and CI at the 30-min 99 
time point were comparable between mouse, pig and human hearts (red and green 100 
symbols). The only metabolites that changed in qualitatively different ways between 101 
species were fumarate and malate (Supplementary Data 1), which both accumulated 102 
during WI in the pig, decreased in the mouse and showed minor changes in the human. 103 
As can be seen there were notable and similar changes in many metabolites for all three 104 
species, including for choline, nicotinamide, alanine, proline, aconitate, branched chain 105 
amino acids and in the breakdown products of purines and pyrimidines.  106 
Succinate increased dramatically during WI in all species (Figs. 2a-c). This 107 
finding was of particular interest because succinate accumulation during ischaemia 108 
contributes to IR injury upon reperfusion via generation of ROS by reverse electron 109 
transport (RET) at mitochondrial complex I3,4. Quantification of succinate levels over 110 
time showed that during WI there was rapid succinate accumulation within 6 min that 111 
increased further and plateaued at about 30 min (Figs. 3a–c). During CI succinate 112 
accumulation was far less, and even after 4h CI — the storage limit for human hearts to 113 
be transplanted — succinate was less than after 6 min WI (Figs. 3a-c). Even after 114 
extending CI of mouse hearts to 12 h the succinate level was still similar to that after 12 115 
min of WI (Fig. 3d). The relative changes (Figs. 3a-c) as well as the absolute succinate 116 
levels (Fig. 3e) were remarkably similar in mouse, pig and human heart tissue. 117 
Cardioplegia slightly decreased succinate levels during WI in the mouse hearts 118 
(Supplementary Fig. 6a), but even so the relative accumulation was still 4 –5-fold above 119 
CI levels, suggesting that succinate accumulation is unrelated to changes in muscle 120 
contraction. As succinate accumulation is driven by the interconversion of fumarate and 121 
succinate by succinate dehydrogenase (SDH) we next assessed the succinate/fumarate ion 122 
intensity ratio (Figs. 3f-h). This showed a significant increase during WI in mouse, with a 123 
less pronounced increase in pig and human, that in all cases were slowed by CI. We 124 
 5
conclude that there is a significant accumulation of succinate during WI in mouse, pig 125 
and human hearts that is greatly slowed by cooling.  126 
Succinate accumulation in ischaemic mouse hearts was proportional to 127 
temperature (Supplementary Fig. 6b). When a mouse heart was transferred to cold static 128 
storage its temperature dropped to ~2˚C within 1 min (Supplementary Fig. 6c), likely 129 
minimising succinate accumulation. However, the much larger human heart (~300 g vs 130 
~150 mg for the mouse) will take far longer to cool during transplantation, potentially 131 
leading to succinate accumulation due to WI. To assess this we measured the core and the 132 
surface temperatures of a pig heart (~300 g) during flushing with cold preservation 133 
solution via the aortic root cannula immediately after cross clamp in conjunction with 134 
topical application of ice ‘slush’ (Fig. 4a), as occurs during human heart transplantation. 135 
The core took ~15 min to reach 4 ˚C, despite using the same rapid cooling procedures 136 
used during clinical heart transplantation. This slow cooling led to significant succinate 137 
accumulation (Fig. 4b). Therefore, the inevitable periods of WI during organ retrieval, 138 
cooling and storage during transplantation will lead to significant succinate accumulation.  139 
Measuring mouse heart temperature during retrieval for transplantation indicated 140 
that after the blood supply was stopped, the organ cooled slowly while the vessels were 141 
being prepared for transplantation, despite frequent topical application of cold saline 142 
(Supplementary Fig. 6d). This period of ischaemia as the organ cooled led to succinate 143 
accumulation that was retained during subsequent cold storage (Supplementary Fig. 6e). 144 
To determine whether the accumulated succinate could contribute to tissue damage by 145 
driving IR injury upon reperfusion during transplantation, we used a mouse model of 146 
syngeneic transplantation, in which a heart is transplanted heterotopically into the 147 
abdomen13,14. During transplantation, there is a further period of ~20 min ischaemia as 148 
the heart is anastomosed to the blood vessels in the recipient mouse. During this time the 149 
heart gradually warmed up, despite cooling by topical saline, leading to a further 150 
accumulation of succinate (Fig. 4c). Within 5 min of reperfusion following 151 
transplantation the succinate level returned to baseline (Fig. 4c). Therefore during 152 
retrieval, storage and transplantation donor hearts accumulate succinate that is rapidly 153 
oxidised upon reperfusion in the recipient.  154 
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To model the slower cooling of a human heart during retrieval, we then assessed 155 
whether increasing the duration of WI (in addition to the ~8 min during retrieval and the 156 
~20 min during anastomosis in the recipient) contributed to damage upon transplantation 157 
(Fig. 4d). Hearts did not survive transplantation when exposed to more than ~12 min WI 158 
after retrieval. Hearts transplanted after a further 12 min WI had increased damage 159 
evaluated 24 h after transplantation by release of troponin (Fig 4e) and mtDNA15,16 (Figs. 160 
4f,g) and by damage to mtDNA within the tissue (Fig. 4h). As the extra period of WI will 161 
increase succinate levels (Fig. 4c), these findings are consistent with increased WI 162 
contributing to heart damage through elevated succinate driving mitochondrial ROS 163 
production upon reperfusion. However, many other factors may contribute to tissue 164 
damage in addition to succinate. Therefore, we next explored the role of succinate 165 
accumulation alone in the absence of other confounding factors associated with WI. 166 
To assess the role of succinate accumulation on heart damage upon 167 
transplantation independently of other effects of WI, we increased heart succinate levels 168 
by infusing bis-acetoxymethyl succinate (AMS)17. AMS generates succinate within cells 169 
that can then be oxidised by SDH17. Hearts were incubated at 37˚C for 20 min, to mimic 170 
the time taken for anastomosis of the heart in the recipient, followed by 30 min CI. 171 
Addition of AMS after CI greatly increased tissue succinate levels above that due to WI 172 
alone due to enhanced hydrolysis of AMS at 37˚C (Supplementary Fig. 6f). AMS-treated 173 
hearts exhibited increase damage upon transplantation, as measured 24 h later by the 174 
release of troponin (Fig. 4e) and mtDNA (Figs. 4f,g) and by damage to mtDNA within 175 
the transplanted heart (Fig. 4h). Infusion of the same amount of bis-acetoxymethyl 176 
fumarate, which readily delivers fumarate within cells (Supplementary Figs. 6g),  did not 177 
lead to damage (Supplementary Figs. 6h,i), indicating that disruption to cardiac damage is 178 
specific to succinate over other TCA cycle intermediates. These findings show that 179 
succinate alone is sufficient to cause extensive damage to the transplanted heart. This is 180 
consistent with succinate accumulation being responsible for at least part of the increased 181 
heart damage caused by 12 min further WI.  182 
Finally, to determine if this increased heart damage due to 12 min further WI was 183 
decreased by inhibiting succinate accumulation and oxidation, we infused dimethyl 184 
malonate (DMM) prior to initiating retrieval and cold storage to load the heart with 185 
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malonate (Fig. 4d, Supplementary Fig. 6j). Hydrolysis of DMM will generate the SDH 186 
inhibitor malonate within the tissues slowing both the accumulation of succinate during 187 
ischaemia (Supplementary Fig. 6k) and its oxidation upon reperfusion, thereby protecting 188 
against IR injury4,18,19. DMM protected the heart against damage measured 24 hours after 189 
transplantation (Figs. 4e-h). Thus, succinate accumulation during WI and its oxidation 190 
upon reperfusion is a significant contributor to IR injury in transplantation and its 191 
amelioration decreases organ injury.  192 
We can draw a number of significant conclusions from our assessment of 193 
metabolic changes during WI and CI in mouse, pig, and human heart. Firstly, metabolism 194 
during WI and CI was comparable between mice, pigs and human hearts, encouraging the 195 
development of therapies using animal models. Secondly, during WI there was a dramatic 196 
decrease in the ATP/ADP ratio that is slowed by CI. The fall in ATP/ADP ratio during 197 
WI was paralleled by the generation of AMP via adenylate kinase, leading to AMP 198 
breakdown and an accumulation of purine and pyrimidine breakdown products. Therefore 199 
a major benefit of CI is preserving the ATP/ADP ratio and preventing loss of adenine 200 
nucleotides, the loss of which likely contributes to increased RET at reperfusion20. 201 
Thirdly, there was a rapid decrease in glycogen with WI and an associated increase in 202 
lactate, consistent with anaerobic glycolysis driving ATP production. This loss of 203 
glycogen and production of lactate was far faster in WI than CI, but interestingly there 204 
was incomplete breakdown of glycogen in WI, suggesting that the rising NADH/NAD+ 205 
ratio and/or the falling ADP level slowed glycolysis and glycogenolysis. Finally, and 206 
most interestingly, succinate accumulated very rapidly in all species during WI. 207 
Ischaemic succinate accumulation most likely arises as a consequence of the build-up of 208 
NADH and other metabolites contributing to succinate  generation by reversal of SDH3,4. 209 
However, further work will be required to assess whether glutaminolysis also contributes 210 
to succinate accumulation during WI, as recently proposed21. This selective accumulation 211 
of succinate over other TCA metabolites during ischaemia may be the consequence of 212 
multiple metabolic reactions that converge on succinate, which cannot be metabolised 213 
further under these conditions, in contrast to other TCA metabolites. 214 
Importantly, succinate accumulation occurred when we simulated donation after 215 
brain stem death (DBD) in which normoxaemic organs are cooled in situ immediately 216 
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after cessation of circulation and are therefore often considered to be exposed to ‘cold 217 
ischaemia’ only. However, these organs are exposed to at least a few minutes of ‘warm 218 
ischaemia’ as the organs become ischaemic and cooling commences, but before the organ 219 
reaches ~2°C. Thus damage caused by WI is an inevitable, albeit not widely recognised, 220 
part of all transplantation despite the widespread reliance on cold flush and storage to 221 
enhance organ preservation.  222 
In summary, in the first application of detailed and time-resolved metabolomics to 223 
transplant surgery we have shown that succinate accumulation is an important but 224 
underappreciated cause of pathology during organ transplantation. We propose that 225 
preventing the accumulation and oxidation of succinate during transplantation with new 226 
therapies and changes in methodology to ensure more rapid cooling will improve the 227 
outcome of transplantation. 228 
 229 
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Methods 303 
 304 
Materials. The composition of UW storage solution used is (mM): potassium 305 
lactobionate, 50; KH2PO4, 25; MgSO4, 5; raffinose, 30; adenosine, 5; glutathione, 3; 306 
allopurinol, 1; and hydroxyethyl starch (50 g/L). The composition of St Thomas’s 307 
cardioplegia solution is: (NaCl 110.0 mM, NaHCO3 10.0 mM, KCl 16.0 mM, MgCl2 308 
16.0 mM, CaCl2 1.2 mM, pH 7.8). Dimethyl malonate was from Thermo Fisher 309 
Scientific, UK. Tissue samples were incubated in polypropylene tubes,  either 1.5 ml 310 
(Ref:72.690.001) or 50 mL (Ref: 62.547.004), both from  Sarstedt, Nümbrecht, Germany. 311 
 312 
Animals. Female mice (C57BL/6J (B6/J) ) of  10 – 20  weeks of  age, weighing 16-22g  313 
were purchased from Charles River Laboratories, UK. Mice were maintained in specific-314 
pathogen-free animal facilities with ad libitum access to food and water. Mice were 315 
picked at random from the same cage  and  assigned to control and experimental arms, 316 
but  no effort was  made to ensure that littermate controls.  Large white male (Landrace) 317 
pigs (45-55 kg) were supplied by Envigo and were acclimatised for a minimum of 7 days 318 
prior to experiments, with ad libitum access to food and water. All animal experiments 319 
were approved by the UK Home Office under the Animals (Scientific Procedures) Act 320 
1986. Mouse experiments were covered by PPL 80/2638.  321 
 322 
Human tissue. Heart biopsies were taken from deceased human DBD donors deemed 323 
unsuitable for cardiac transplantation aged 36-69 (Table S1). Informed consent for the 324 
use of the human tissue for this project was provided by the donors' families. Ethical 325 
approval for the studies was obtained from NRES Committee East of England – 326 
Cambridge South (REC Reference 15/EE/0152). 327 
 328 
Mouse heart experiments. C57BL/6 mice (female) were anaesthetised with isoflurane 329 
(Abbott Laboratories, US) 2 MAC and O2 at 2 L/min. Heparin (100 µL bolus (25 iU) Leo 330 
Pharma A/S, Ballerup, Denmark) was administered intravenously into the inferior vena 331 
cava (IVC) prior to retrieval. Hearts were excised by division of the major vessels. To 332 
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measure metabolite concentrations in the heart under baseline conditions in vivo, the still-333 
beating heart of an anesthetised mouse was rapidly frozen using Wollenberg clamps at 334 
liquid nitrogen (LN2) temperature, taking < 5 s to go from the beating heart to frozen. For 335 
cold ischemia (CI) the heart was placed directly in UW solution at ~2°C. Under these 336 
conditions the ventricles pulsed once or twice before stopping. For warm ischaemia (WI) 337 
the excised heart was left in the abdomen of the animal, with the abdominal wound 338 
closed and the animal maintained on a 37°C heating pad with a relayed rectal temperature 339 
probe. For analysis at various times the whole heart was clamped at LN2 temperature as 340 
above. At various times the tissues were rapidly snap-frozen and stored at -80˚C until 341 
analysis. Fully oxygenated ‘normoxic’ heart tissue, snap-frozen immediately upon 342 
cessation of circulation, was used as control. Tissues were stored at -80°C until extraction 343 
and analysis. 344 
To replicate heart retrieval with retrograde flushing of the coronary vessels during 345 
retrieval (Supplementary Fig. 4e) the donor animal was prepared as described above. 346 
Following exsanguination, the great vessels were prepared for implantation22. The 347 
thoracic cavity was entered by dividing the diaphragm and adequate exposure achieved 348 
by dividing the ribs laterally up to the thoracic inlet and retracting the anterior rib cage 349 
cranially. The IVC or caudal caval vein, left SVC or cranial caval vein and right SVC or 350 
cranial caval vein were ligated with silk ties. The fat and connective tissue was dissected 351 
between the aorta and pulmonary artery prior to division of the ascending aorta at the 352 
level of the innominate artery. If the heart were to be flushed, the innominate, right 353 
carotid and right brachiocephalic artery were ligated and divided. The descending aorta 354 
was then divided. The left and right pulmonary arteries were divided adjacent to their 355 
bifurcation and the connecting vessel wall divided to create a single opening. During 356 
dissection and ligation of vessels the heart was topically cooled intermittently with 0.9% 357 
w/v sodium chloride kept on ice. Following ligation of the pulmonary artery blood 358 
remaining in the ventricles was manually expressed. The pulmonary veins were ligated en 359 
masse and the heart excised. 500 µL Soltran® (Baxter Healthcare) was then injected via a 360 
fine bore (0.28 x 0.165 mm) polyethene tube (Portex tubing, Smith Medical International 361 
Ltd, UK) into the aorta to antegrade flush the coronary arteries. The prepared hearts were 362 
then placed in UW solution at ~2°C for various durations of CI after which, the whole 363 
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heart was clamped at LN2 temperature as above. For other mouse heart experiments, a 364 
500 µL bolus of St Thomas’ Cardioplegia solution was administered by IVC injection. 365 
Complete cessation of a heart beat was observed visually within 2 seconds. Dimethyl 366 
malonate (DMM) was administered as an infusion over 10 minutes via the IVC by a 367 
microinfusion pump (Kd Scientific, Holliston, MA, USA) using a fine bore (0.28 x 0.165 368 
mm) polyethene tube (Portex tubing, Smith Medical International Ltd, UK) prior to the 369 
administration of cardioplegia. Control animals were infused with 0.9% w/v sodium 370 
chloride by microinfusion pump (Kd Scientific, Holliston, MA, USA). 371 
Bis(acetoxymethyl)succinate (with 5% DMSO)  or bis(acetoxymethyl)fumarate (with 372 
30% DMSO)  was administered in the cardioplegia solution. Hearts from donor mice 373 
were transplanted heterotopically into a syngeneic recipient13,14. The donor heart was 374 
transplanted heterotopically into the abdomen of the recipient animal using a 375 
microsurgical technique. The recipient mouse was weighed before being anaesthetised 376 
with isoflurane (Abbott Laboratories, US) and oxygen at 2 l/min. The skin at the 377 
operative site was shaved and prepped with chlorhexidine gluconate (4% w/v). Analgesia 378 
was administered by subcutaneous injection of 100 μl Temgesic (Indivior, UK) diluted in 379 
500 μl 0.9% w/v sodium chloride to the nape of the animal. The animal was transferred to 380 
the operating table, secured in a supine position using adhesive tape and the animal’s 381 
rectal temperature was measured continuously using a rectal thermometer and maintained 382 
at 37°C ± 1°C using a relayed variable heat mat. A midline laparotomy was performed 383 
and the abdominal and exposure achieved using a self-retaining retractor. The urinary 384 
bladder was emptied by gentle pressure using sterile cotton buds. The small bowel and 385 
colon were deflected superiorly and a small strip of connective tissue divided to facilitate 386 
this manoeuvre. The abdominal viscera were retracted and covered with moistened sterile 387 
gauze to provide adequate exposure to the abdominal aorta and IVC and adequate 388 
moisture maintained throughout the procedure by periodic topical irrigation. The 389 
connective tissue overlying the abdominal aorta and IVC was divided by a combination 390 
of sharp and blunt dissection. The posterior lumbar vessels were identified and ligated 391 
using 7-0 silk ties.  Non-crushing vascular clamps were applied to the vessels distal to the 392 
renal vessels and proximal to their bifurcation. The IVC was emptied via a venotomy 393 
created with a 31-gauge needle. An arteriotomy was then made in the aorta and this was 394 
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extended using micro-surgical scissors to match the diameter of the donor aorta. The 395 
lumen was flushed with 0.9% w/v sodium chloride to remove any remaining blood and 396 
clots. The donor heart was then retrieved from cold storage and placed into the right side 397 
of the recipient’s abdomen with the remnant ascending aorta adjacent to the arteriotomy. 398 
A small piece of gauze moistened with cold (1-2°C) 0.9% w/v sodium chloride was 399 
placed over the heart to minimise warming and periodic topical application of (1-2°C) 400 
0.9% w/v sodium chloride was applied to the donor heart during the procedure. Cranial 401 
and caudal stay sutures were placed between the donor and recipient vessels using 10-0 402 
nylon BearTM surgical suture on a round bodied 4 mm (3/8) needle (Bear Medic Corp., 403 
Tokyo, Japan). A continuous end-to-side anastomosis run in a counter clockwise 404 
direction was then constructed from the caudal stay suture. After completing one side of 405 
the anastomosis, the heart was turned to the animal’s left side to enable access and 406 
completion of the anastomosis. The venotomy on the IVC was then extended in a cranial 407 
direction. The pulmonary artery was anastomosed in a similar fashion using 10-0 nylon 408 
BearTM surgical suture. Over tightening of sutures was minimised to ensure there was no 409 
constriction of the anastomosis. Cut pieces of Surgicel (Ethicon, Johnson and Johnson, 410 
US) were applied around the anastomosis. The distal clamp was removed followed by the 411 
proximal clamp. Satisfactory perfusion was indicated by a bright red heart displaying 412 
strong rhythmic contractions and warmed topical 0.9% w/v sodium chloride was applied 413 
to the heart to expedite this process. The abdominal fascia and skin were closed in two 414 
layers with continuous 5-0 vicrylTM (Ethicon, Johnson and Johnson, UK).  Following 415 
reperfusion and closure of the midline wound 500 μl of 0.9% sterile saline was injected 416 
subcutaneously.  Animals were recovered in an incubator at 28°C overnight on soft, dry 417 
bedding with food and water. Animals that developed post-operative hind limb paralysis 418 
were killed immediately. The next day animals were returned to standard cages with 419 
standard rodent diets. All transplanted hearts contracted spontaneously following 420 
reperfusion. Hearts were excised by division of the anastomosed vessels at chosen time 421 
points after reperfusion and the hearts were snap frozen using a Wollenberg clamp and 422 
stored at -80°C until tissue extraction. Animals were randomly allocated to control and 423 
treatment groups and the analysis performed blinded to the experimental groups. 424 
 425 
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Pig heart experiments. Pigs were pre-medicated with intramuscular ketamine (10 426 
mg.kg-1), medetomidine (0.02 mg.kg-1) and midazolam (0.1 mg.kg-1). A peripheral 427 
intravenous catheter was placed in the marginal ear vein and anaesthesia was induced 428 
with propofol. Pigs were intubated and 100% oxygen supplied with intermittent positive 429 
pressure ventilation provided to maintain normocapnia. Anaesthesia was maintained with 430 
continuous infusions of propofol (starting at 10 mg.kg-1hr-1 and titrating down to effect) 431 
and either remifentanil (starting at 2.4 µg.kg-1hr-1 and titrating up to effect) or alfentanil 432 
(starting at 30 µg.kg-1hr-1 and titrating up to effect). If required, isoflurane was provided 433 
at approximately 2% to maintain anaesthesia. Saline was administered intravenously at 434 
approximately 10 ml.kg-1hr-1. During anaesthesia a Datex Ohmeda Cardiocap patient 435 
monitoring system was used to monitor ECG waveform, pulse oximetry, temperature and 436 
capnography parameters. Immediately following euthanisation (induced rapidly with an 437 
overdose of approximately 200 mg.kg-1 pentobarbitone) the thoracic cavity was accessed 438 
through the diaphragm and the apex of the heart (~20-30 g) was amputated with a scalpel 439 
under terminal anaesthesia. We note that this retrieval procedure, particularly the use of 440 
anaesthesia is unavoidable, but is slightly different from that used in human 441 
transplantation. A full thickness tissue sample (~120 mg) was immediately clamped 442 
frozen using Wollenberger clamps at LN2 temperature, taking < 5 s from cessation of 443 
aortic pulse to freezing. The rest of the tissue was cut in half with one half transferred to 444 
cold storage solution and then further cut into smaller pieces (~120 mg) which were then 445 
stored in UW storage solution at ~2˚C. The other half of the heart tissue was also cut into 446 
sections (~120 mg) which were stored in a humidified atmosphere at 37˚C by suspension 447 
above saline in sealed Eppendorf tubes. At various times the tissues were then frozen 448 
using Wollenberger clamps at LN2 temperature and stored at -80˚C until analysis.  449 
To measure the core and surface temperature and tissue succinate of the porcine 450 
heart following rapid retrieval and back-table flush the pig was anaesthetised and 451 
euthanized as described above. After circulatory arrest was confirmed the thoracic cavity 452 
was then rapidly accessed through an incision in the diaphragm and heart was rapidly 453 
retrieved by division of the great vessels. On removal from the thoracic cavity, a ‘time-454 
zero’ surface wedge and core needle biopsy were immediately taken and clamp frozen in 455 
liquid nitrogen. The core and surface temperature probes (K-type thermocouple, Hanna 456 
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Instruments, Bedfordshire) were then inserted into the heart. The core temperature probe 457 
was inserted into the septum using a hollow biopsy needle. A small incision was made in 458 
the surface of the right ventricle in which the surface probe was inserted and sutured in 459 
place. This step took between 1-2 minutes to complete. Temperature recording was then 460 
commenced and the heart was submerged in a pre-prepared dish of slushed ice and UW 461 
solution. The temperature was recorded every second by a digital data-logger connected 462 
to the temperature probe (EL-USB-2 LC, Lascar Electronics, Wiltshire). A 14G French 463 
cannula was used to flush the coronary circulation with cold UW solution. A third 464 
temperature probe was used to measure the temperature of the solution as it entered the 465 
heart. The coronary sinuses at the base of the aorta were alternately cannulated and 466 
effective flushing of the circulation could be directly observed by flushing of blood with 467 
preservation solution in the surface coronary vessels. The time taken to flush the heart 468 
with 500 mL cold UW solution was recorded in each case. Further surface wedge and 469 
core-needle biopsies were taken at 6, 12 and 30 minutes.  470 
 471 
Human heart experiments. Human donation after brainstem death (DBD) donors 472 
undergoing abdominal multi-organ retrieval but for whom cardiothoracic organs had been 473 
declined for transplantation were identified (Supplementary Table 1). Appropriate 474 
consent for research was obtained from the donor families. A thoracotomy was performed 475 
as a routine part of the abdominal organ retrieval procedure, thus allowing a sample (~20-476 
30 g) of myocardium from the apex of the still-beating heart to be removed at the same 477 
time as exsanguination and cross clamp of the donor, during organ retrieval. The heart 478 
tissue was frozen in Wollenberg clamps, taking <5s to go from the beating oxygenated 479 
heart to frozen sample. After this base line sample, further samples (~120 mg) were 480 
removed, maintained at either 37˚C or ~2˚C as described for the pig tissue, and at various 481 
times frozen and stored at -80˚C.  482 
 483 
Tissue extraction and metabolite analysis by liquid chromatography coupled to 484 
mass spectrometry (LC-MS). Frozen tissue samples were weighed into Precellys tubes 485 
prefilled with ceramic beads (Stretton Scientific Ltd., Derbyshire, UK), and an exact 486 
volume of extraction solution (50% methanol, 30% acetonitrile and 20% water) was 487 
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added to obtain 40 mg specimen per mL of extraction solution thus allowing for 488 
comparisons between experimental conditions for the same metabolite. Samples were 489 
lysed using a Precellys®24 tissue homogeniser (Bertin Corp, Rockville, MD 20850, 490 
USA. 5500 rpm 15 seconds x 2) and then centrifuged (16,162 x g for 10 min at 4°C). The 491 
supernatant was transferred to glass vials (Microsolv Technology Corp., Leland, NC 492 
28451, USA) and stored at -80°C until LC-MS analysis. 493 
LC-MS analyses were performed on a Q Exactive Orbitrap (Thermo Scientific) 494 
mass spectrometer coupled to an Ultimate 3000 RSLC system (Dionex). The liquid 495 
chromatography system was fitted with either a ZIC-HILIC column (150 mm × 4.6 mm) 496 
or a ZIC-pHILIC column (150 mm × 2.1 mm) and respective guard columns (20 mm × 497 
2.1 mm) (all Merck, Germany)23. For the  ZIC-HILIC column the flow rate was 300 498 
µl/min and the gradient comprised   0.1% formic acid/water and 0.1% formic acid 499 
/acetonitrile as follows (time (min), % acetonitrile): 0, 80; 12, 50; 26, 50; 28, 20; 36, 20; 500 
37, 80;45, 80. For the  ZIC-pHILIC column the flow rate was 200 µl/min and the gradient 501 
comprised   20 mM (NH4)2CO3, pH 9.4 and acetonitrile as follows (time (min), % 502 
acetonitrile): 0, 80; 2, 80; 17, 20; 17.1, 80; 19.1, 80; 22.1, 80;22.2, 80, with an increase in 503 
flow rate to 400 µl/min from 19.1 to 22.1. The mass spectrometer was operated in full 504 
MS and polarity switching mode. Samples were randomised in order to avoid bias due to 505 
machine drift and processed blindly. The acquired spectra were analysed using XCalibur 506 
Qual and and XCalibur Quan Browser software (Thermo Fisher Scientific) by referencing 507 
to an internal library of compounds. Absolute quantification of selected metabolites was 508 
performed by interpolation of the corresponding standard curve obtained from serial 509 
dilutions of commercially available standards (Sigma Aldrich) running with the same 510 
batch of samples. All the extractions and analyses were done under the same conditions 511 
and relative to the same internal standard. The NADH/NAD+, lactate/pyruvate and 512 
succinate/fumarate ratios are presented as relative changes in the ratio of the ion current 513 
for these metabolites, which is proportional to, but not the same as, the true ratio of the 514 
metabolite levels.  515 
LC-MS/MS analysis of succinate and malonate from pig, mouse and human 516 
temperature studies and fumarate delivery from bis-acetoxymethyl fumarate in cells was 517 
performed using an LCMS-8060 mass spectrometer (Shimadzu, UK) with a Nexera X2 518 
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UHPLC system (Shimadzu, UK). Samples were stored in a refrigerated autosampler (4 519 
°C) upon injection of 5 μl into a 15 μl flow through needle. Separation was achieved 520 
using a SeQuant® ZIC®-HILIC column (3.5 μm, 100 Å, 150 x 2.1 mm, 30 °C column 521 
temperature; MerckMillipore, UK) with a ZIC®-HILIC guard column (200 Å, 1 x 5mm). 522 
A flow rate of 200 μl/min was used with mobile phases of A) 100 mM ammonium 523 
acetate (pH 6.9) and B) 100% acetonitrile. A gradient of 0-0.1 min, 80% MS buffer B; 524 
0.1-4 min, 80%-20% B; 4-10 min, 20% B, 10-11 min, 20%-80% B; 11-15 min, 80% B 525 
was used. The mass spectrometer was operated in negative ion mode with multiple 526 
reaction monitoring (MRM) and spectra were acquired using Labsolutions software 527 
(Shimadzu, UK), with compound quantities calculated from relevant standard curves 528 
(succinate, malonate or fumarate) in MS extraction buffer and comparing against 13C-529 
succinate (for succinate and fumarate) or 13C-malonate (for malonate) internal standards. 530 
Metabolomic data have been uploaded  as study MTBLS1085 to MetaboLights 531 
(https://www.ebi.ac.uk/metabolights). 532 
 533 
Tissue analysis for ATP/ADP ratio. ATP and ADP concentrations were measured using 534 
a Luciferase based assay 24. Frozen tissue samples were homogenised in ice-cold 535 
perchloric acid extractant (3% v/v HClO4, 2 mM Na2EDTA, 0.5% Triton X-100). The 536 
supernatant was diluted to a concentration of 1 mg frozen tissue /ml. Samples, ATP and 537 
ADP standards were pH neutralized using a potassium hydroxide solution (2 M KOH, 538 
2 mM Na2EDTA, 50 mM MOPS), vortexed until formation of a white precipitate 539 
(KClO4), then centrifuged (17, 000 X g for 1 min at 4°C). For ADP measurements, 250 540 
µl neutralised sample supernatant was mixed with 250 µl ATP sulfurylase assay buffer 541 
(20 mM Na2MoO4, 5 mM GMP, 0.2 U ATP sulfurylase (New England Biolabs), in Tris-542 
HCl buffer (100 mM Tris-HCl, 10 mM MgCl2 (pH 8.0))), incubated for 30 min at 30oC 543 
with shaking (500 rpm), heated at 100˚C for 5 min and then cooled on ice. Standards (100 544 
µl), samples for ATP measurement (100 µl) or samples for ADP measurement (200 µl) 545 
(in duplicate) were added to 400 µl Tris-acetate (TA) buffer (100 mM Tris, 2 mM 546 
Na2EDTA, 50 mM MgCl2, pH 7.75 with glacial acetic acid) in luminometer tubes. 10 µl 547 
pyruvate kinase solution (100 mM PEP, 6 U pyruvate kinase suspension (Sigma # 548 
P1506)) were added to one set of samples for ADP measurement and incubated for 30 549 
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min at 25°C in the dark to convert ADP to ATP. The other duplicate tube (without 550 
addition of pyruvate kinase solution) served as an ADP ‘blank’ value. The samples were 551 
then all assayed for ATP content in a Berthold AutoLumat Plus luminometer by addition 552 
of 100 µl Luciferase/Luciferin Solution (7.5 mM DTT, 0.4 mg/ml BSA, 1.92 µg 553 
luciferase/ml (SIGMA #L9506), 120 µM D-luciferin (SIGMA # L9504), made in TA 554 
buffer (25% v/v glycerol)), delivered via auto injection, protected from light. 555 
Bioluminescence of the ATP-dependent luciferase activity was measured for 45 s post 556 
injection and the data quantified against standard curves. 557 
 558 
Glycogen assay. The glycogen assay protocol was adapted from25, measuring the 559 
production of NA(D)PH during the oxidation of glycogen-derived glucose to 6-560 
phosphogluconate. Frozen tissue (5-10 mg) was minced finely before being treated with 561 
250 µl hot acid (2 M HCl; 100°C) or alkali (2 M NaOH; 100°C) to hydrolyse glycogen or 562 
as an unhydrolysed control respectively (100 °C, 1 h, vigorous shaking every 10 min). 563 
Samples were subsequently cooled to RT and neutralised to pH 7 with either 2 M NaOH 564 
or HCl and the addition of 500 µl 400 mM Tris (pH 7.4). Neutralised samples were 565 
vortexed before centrifuging (17,000 x g, 10 min, RT). 60 µl of sample supernatant was 566 
plated in duplicate in a 96-well plate together with a glucose standard curve (0,10, 20, 40, 567 
80, 160 µg glucose/ml). 200 µl glucose assay reagent (G3293, Sigma) was added to each 568 
well and the plate incubated (5 min, RT) prior to measuring absorbance at 340 nm in a 569 
Spectramax Plus 384 plate reader (Molecular Devices, UK). The average absorbance of 570 
each sample was interpolated using the standard curve and multiplied by the final volume 571 
after pH adjustment to give µg of glycogen (or glucose for NaOH control) in original 572 
sample. This was divided by the weight of tissue added and the NaOH control was 573 
subtracted from the HCl sample to give µg glycogen per mg frozen tissue. 574 
 575 
Synthesis of bis(acetoxymethyl)succinate. Bis(acetoxymethyl)succinate (202 mg, 0.769 576 
mmol) was prepared in 91% yield from succinic acid (100 mg, 0.847 mmol) in a similar 577 
way to Ehinger et al.,17 except acetonitrile was used as solvent and after 16 h reaction the 578 
solvent was evaporated and the crude mixture purified by column chromatography [SiO2, 579 
hexane-ethyl acetate (7:3)]. Rf [SiO2, hexane-ethyl acetate (7:3)] = 0.24. νmax (ATR): 580 
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1751 (CO) cm-1. δH (400 MHz, CDCl3): 5.75 (4H, s, OCH2O), 2.71 (4H, s, CH2CO2), 581 
2.12 (6H, s, CH3). δC (126 MHz, CDCl3): 170.93 (2C, s, CO), 169.71 (2C, s, CO), 79.38 582 
(2C, s, CH2O), 28.66 (2C, s, CH2CO), 20.80 (2C, s, CH3). LRMS (ESI+): 285 (MNa+, 583 
100%). HRMS (ESI+): 285.0579. C10H14NaO8+ requires (MNa+), 285.0581. 1H NMR and 584 
13C NMR data agree with literature17. See Supplementary Fig. 7. The original data has 585 
been deposited at http://dx.doi.org/10.5525/gla.researchdata.646.  586 
 587 
Synthesis of bis(acetoxymethyl) fumarate. Bromomethyl acetate (300 μl, 3.06 mmol, 588 
2.2 eq) was added to a solution of fumaric acid (161 mg, 1.39 mmol, 1.0 eq) and 589 
diisopropylamine (605 μl, 3.47 mmol, 2.5 eq) in dry acetonitrile (8 ml) cooled to 0 °C 590 
under argon. The solution was allowed to warm to room temperature, stirred overnight, 591 
concentrated under vacuum and purified by column chromatography [SiO2, hexane-ethyl 592 
acetate (80:20) to (50:50)] to give the bis-AM ester as a white solid (310 mg, 86%). Rf 593 
[SiO2, hexane-ethyl acetate (7:3)] = 0.31. M.p. 89-91°C. νmax (ATR)/cm-1: 1755 (CO2), 594 
1728 (CO2), 977 (C=C). δH (400 MHz: CDCl3): 2.12 (6H, s, CH3), 5.84 (CH2), 6.92 595 
(CH). δC (100 MHz: CDCl3): 20.76 (CH3), 79.80 (CH2), 133.98 (CH), 163.27 (C), 169.51 596 
(C). HRMS (ESI+): 283.0423. C10H12NaO8 requires (MNa+), 283.0424. See 597 
Supplementary Fig. 7. The original data have been deposited at 598 
  http://dx.doi.org/10.5525/gla.researchdata.646. 599 
 600 
Troponin measurement. Non-heparinised IVC blood samples were taken immediately 601 
prior to graft harvest. Samples were left for 30 mins at room temperature to ensure 602 
adequate clot propagation, centrifuged (2000 x g for 10 minutes) and serum apportioned 603 
into aliquots and stored at -80°C. Serum troponin-I was measured using a commercially 604 
available mouse cardiac troponin-I ELISA (KT-470, Kamiya Biomedical Company, 605 
Seattle, WA, USA) by the Core Biomedical Analysis Laboratory, Addenbrooke’s 606 
Hospital, Cambridge.  607 
 608 
Measurement of mtDNA release. The release of mitochondrial and nuclear DNA into 609 
the circulation was assessed using the droplet digital polymerase chain reaction (ddPCR). 610 
Serum samples were centrifuged (1600 g for 10 min) and the supernatant was then 611 
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centrifuged once more (16 000 g for 10 min) and DNA isolated using the DNeasy Blood 612 
kit (QIAGEN) according to the manufacturer’s instructions, with step 3, the addition of 613 
lysis buffer AL, omitted. DNA was quantified using a ‘Nanodrop’ system and diluted to 1 614 
ng/µL in elution buffer. For mtDNA the ND5 gene was assessed using the following 615 
primers: F- CTGCTCTTTCCCAGACGAGG; R- AAGGCCACTTATCACCAGC. For 616 
nuclear DNA the β-actin gene was assessed, using F-617 
ACCTAATTAAACACATCAACTTCCC; R- GACTCAGTGCCAGGTTGTAA. Each 618 
PCR reaction (22 µL) comprised 1 µL (= 1 ng) DNA template, 11 µL ddPCR 619 
Supermix (no dUTP) containing Taq, 314 nM of each primer, and 210 nM of the HEX-620 
ND5 probe (ACACCACCACATCAATCAAATTCTCCTTCA) and of the FAM-β-actin 621 
probe (ATTGCCTTTCTGACTAGGTG) and then made up to 22 µl with H2O. The 622 
BIORAD ddPCR AutoDG was used to generate ddPCR droplets and the plate was sealed 623 
at 174˚C before the PCR was run in a BIORAD C1000 Thermo Cycler: 95˚C at 10 min 624 
followed by 40 cycles of 30 sec at 95˚C and 1 min at 58˚C and then 95˚C at 10 min. After 625 
completion of the PCR, the fluorescence of the FAM and HEX probes was measured 626 
using the BIORAD QX200 Droplet Reader and analysed using the BIORAD Quantilife 627 
software and Excel. 628 
 629 
QPCR assay for mtDNA damage. Quantitative PCR to detect murine mitochondrial 630 
DNA lesions was based on26 and performed using following primers at 10 µM: forward 631 
primer FWD: 5’-GCC AGC CTG ACC CAT AGC CAT AAT-3’. Reverse primer for the 632 
long 10090 bp PCR product: REV: 5’-GAG AGA TTT TAT GGG TGT AAT GCG G-3’. 633 
Reverse primer for the short 127 bp PCR product: REV: 5’- GCC GGC TGC GTA TTC 634 
TAC GTT A -3’. Sample DNA was extracted using the QIAmp blood and tissue kit 635 
following the provided instructions. QPCR was performed on 15 ng DNA in 35 µl 636 
reactions on a PCR thermocycler (Biometra). 1 U TaKaRa LA Taq was used per reaction. 637 
PCR master mix was prepared following the TaKaRa LA Taq instructions. Linearity of 638 
the PCR reaction was confirmed for each sample by running a 1:2 diluted sample 639 
simultaneously. Cycling parameters for the short reaction were 94ºC for 5 minutes 640 
followed by 16 cycles of 94ºC for 30s, 64ºC for 45s, 72ºC for 45s, followed by 72ºC for 641 
10 minutes. Conditions for the long amplification were 94ºC for 5 minutes followed by 642 
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18 cycles of 94ºC for 15s and 64ºC for 12 minutes, followed by 72ºC for 10 minutes. The 643 
PCR reaction was confirmed on 1% agarose gels and concentrations of the PCR product 644 
were determined by measuring the emission of the samples at 488 nm and excitation at 645 
525 nm after picogreen addition at 1:200 dilution.  646 
 647 
Cell culture. C2C12 mouse myoblast cells were plated at 300,000 cells/well in 6-well 648 
plates and left to adhere overnight. The following day, cells were treated with 0 (DMSO 649 
vehicle control), 0.25, 0.5 or 1 mM fumarate-AM diester for 30 min at 37 °C. Cells were 650 
washed 4 times with ice-cold PBS prior to extracting with 500 µl extraction buffer 651 
containing 13C-succinate internal standard for 15 min on dry ice. Cells were scraped and 652 
transferred to microcentrifuge tubes prior to agitating (15 min, 4 °C, 1000 rpm), then 653 
incubating (-20 °C, 1 h). Samples were centrifuged (17,000 x g, 10 min, 4 °C), the 654 
supernatant transferred to fresh microcentrifuge tubes and recentrifuged (17,000 x g, 10 655 
min, 4 °C). The resulting supernatant was transferred to glass MS vials and stored at -80 656 
°C until analysis by LC-MS/MS. Fumarate levels were determined by interpolation of a 657 
fumarate standard curve and normalised to cellular protein by BCA assay of a parallel 658 
treated plate. 659 
 660 
Statistics and experimental design. All data in figures are presented as mean values ± 661 
SEM unless otherwise stated. Statistical analysis was performed between two groups 662 
using Student’s t-test with sometimes using Sidak’s post-test for multiple comparisons, 663 
and between multiple groups by one-way analysis of variance (ANOVA) or two-way 664 
ANOVA with Bonferroni’s or Tukey’s multiple comparison testing. A P value of less 665 
than 0.05 was considered significant. For Fig 2, fold changes in metabolite abundances 666 
(and their statistical significance) between time points were calculated by using linear 667 
modelling with an empirical Bayes approach as implemented in the 'limma' package of R 668 
(ref 27). Regularised logs were taken of the abundance measurements of each metabolite, 669 
then the targets and the design matrix were defined for groups of samples to be 670 
compared, and the data fitted to a linear model. Contrasts were defined and significantly 671 
affected metabolites were identified from the fitted model by using their p-values, 672 
adjusting for multiple-testing by using the Benjamini0Hochberg procedure. Volcano plots 673 
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were produced by plotting the fold-change of each metabolite versus its adjusted p-value 674 
in R. 675 
 676 
Data availability.  Metabolomic data have been uploaded  as study MTBLS1085 to 677 
MetaboLights (https://www.ebi.ac.uk/metabolights). The original synthetic chemistry 678 
data have been deposited at  http://dx.doi.org/10.5525/gla.researchdata.646. Other data 679 
that support the findings of this study are available  680 
Reporting Summary. Further information on research design is available in the Nature 681 
Research Reporting Summary linked to this article.  682 
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Figure legends 710 
 711 
Fig. 1 | The cardiac ATP/ADP ratio during WI and CI a, A schematic illustrating the 712 
experimental design mimicking ischaemia during transplantation. The whole mouse heart 713 
(~150 – 180 mg), or sections from the transected apex of the pig or human heart (~120 714 
mg) were either immediately clamped frozen at liquid nitrogen temperature to generate a 715 
baseline sample under fully oxygenated “normoxic” conditions, or incubated to induce 716 
warm ischaemia (WI, 37°C) or cold ischaemia (CI) (~2°C ) for the indicated times prior 717 
to freeze clamping. Tissues were then extracted and metabolites assayed ATP and ADP 718 
were determined in heart tissue after various times of WI or CI. b-d, The ATP/ADP ratio 719 
for b mouse, c pig and d human. e-g, The sum of ATP and ADP (nmol/mg wet weight) 720 
for e mouse, f pig and g human. Data are means ± SEM, N =  5 (pig), 4 (human). For b 721 
and  e  data are means ± SEM, WI 6 and CI 240 min,  N = 11; WI 0, 12, 30 and CI 0 min,  722 
N = 9; CI 6 min,  N = 7; CI 12 min,  N = 4; CI 30 min,  N = 3.  723 
 724 
Fig. 2 | Volcano plots of metabolites that change significantly between 30 min WI 725 
and CI. Volcano plots showing -log10 of the adjusted p value plotted against the Log2 of 726 
the fold-change in metabolite abundance between 30 min WI and 30 min CI for a mouse 727 
(N = 5), b pig ( n = 5) and c human (N = 4). Fold-changes and p-values between time 728 
points were calculated by using linear modelling with an empirical Bayes approach as 729 
implemented in the 'limma' package of R, adjusting for multiple-testing by using the 730 
Benjamini-Hochberg procedure. Metabolites that changed in the same way in all three 731 
species are in red. Metabolites that changed in the same way in two of the species but 732 
were not detected, or did not change markedly, in the third are in green. 733 
Proprionylcarnitine, propcarn; acetyl carnitine, acetylcarn; succinyl adenosine, succaden; 734 
3-hydroxybutyrate, 3HB; pyroglutamic acid, pyroglu; cysteine, cys.  735 
Fig. 3 | Succinate levels in the heart during WI and CI. a-d, Fold change in succinate 736 
abundance under WI or CI, relative to normoxic heart tissue in a, d mouse (n = 6), b pig 737 
(n = 4) c human (n = 4). Data are means ± SEM. For a-c significant difference between 738 
groups were measured by two way ANOVA with multiple comparisons at individual 739 
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points by Sidak test (* P < 0.05, ** P < 0.01 *** P < 0.001, **** P < 0.0001). e, 740 
Absolute succinate concentrations as described in a – d.  Data are means ± SEM. Mouse 741 
(n = 6), pig (n = 4) human (n = 4). f-h, Relative change in succinate/fumarate ratio under 742 
WI or CI, compared to normoxic heart tissue. Data are means ± SEM. Mouse (n = 6), pig 743 
(n = 4) human (n = 4). These data are presented as relative changes in the ratio of the ion 744 
current for these metabolites, which is proportional to, but not the same as, the true ratio 745 
of the metabolite levels.  746 
Fig. 4 | Preventing pathological consequences of succinate metabolism during heart 747 
transplantation. a, Surface and core temperature of pig heart during flush with cold UW 748 
solution. Following retrieval the heart was flushed with cold solution and  immersed in 749 
slushed ice. The mean temperature (n = 4) every 10 s  is shown ± SEM (shaded). The 750 
inset shows the temperature probes. b, Surface and core succinate of the pig heart treated 751 
as in a. Core and surface tissue biopsies were taken at 0, 6, 12 and 30 minutes, frozen and  752 
succinate concentration measured (n = 3, Data are means ± SEM). *P < 0.05, by a two-753 
way ANOVA with Sidak's multiple comparison test. c, Succinate concentration in the 754 
mouse heart after standard retrieval and 30 min CIT (‘Isch.’), after standard retrieval and 755 
30 min CIT and anastomosis (‘Isch. + Impl.’), and finally after 5 min reperfusion 756 
(‘Reper.’). Data mean ± SEM (Cont and Isch + Impl, n = 6; Isch, n = 4; Reper, n = 3). 757 
Compared to control (Cont.) by one-way ANOVA with Bonferroni multiple comparisons 758 
tests (***P < 0.001, ****P < 0.0001). d, Schematic of heterotopic heart transplantation in 759 
mice, with a further 12 min WI after retrieval, followed by 30 min cold storage. e-g, 760 
Hearts were infused with DMM (3.4 mg) or saline prior to cardioplegia and then exposed 761 
to 12 min WI, and then stored cold for 30 min, or infused with cardioplegia solution ± 762 
AMS (3.2 mg), followed by cold storage for 30 min. All hearts were then transplanted 763 
into recipients and 24 h later serum troponin e, mtDNA f, or mtDNA/nDNA ratio g, were 764 
measured. h, mtDNA damage in the donor heart was measured 24 h after transplantation 765 
by a PCR assay in which the greater the ratio of amplification the less damage to the 766 
mtDNA.  e -g  (-WI, n=20; +AMS, n=5; +WI, n= 24; +DMM, n= 4) h (Cont, n=8; -WI, 767 
n=4; +AMS, n=5; +WI, n= 7; +DMM, n= 8). Data are means ± SEM). * P < 0.05, **P < 768 
0.01, ****P < 0.0001 by one-sided unpaired t-test with Welch’s correction.  769 
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